



Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets
Boudesco et al
Now reading:
Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets
Author
Boudesco et al
Date
Today's RA therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction, which is exactly what we're working to build.
At IMMUNOLOGY2026, Graph's co-founder and VP Immunology Christophe Boudesco presented the latest results from Graph's Functional Immune Manifold (FIM): a platform that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases.
The crux of our work is a generalized approach that merges large-scale functional profiling with sparse transcriptomic data. By combining functional responses with existing priors, we identify context-dependent, biomarker-stratified targets - the kind built for curative intent, not chronic management.
It's a patient-first, clinically linked approach to I&I discovery. And we're quickly advancing candidates into validation.
View our full poster here
Today's RA therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction, which is exactly what we're working to build.
At IMMUNOLOGY2026, Graph's co-founder and VP Immunology Christophe Boudesco presented the latest results from Graph's Functional Immune Manifold (FIM): a platform that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases.
The crux of our work is a generalized approach that merges large-scale functional profiling with sparse transcriptomic data. By combining functional responses with existing priors, we identify context-dependent, biomarker-stratified targets - the kind built for curative intent, not chronic management.
It's a patient-first, clinically linked approach to I&I discovery. And we're quickly advancing candidates into validation.
View our full poster here
Read More
Graph Therapeutics Brings Total Funding to Over $10 Million to Advance Therapeutics Programs in Inflammation and Immunology
Graph Therapeutics Brings Total Funding to Over $10 Million to Advance Therapeutics Programs in Inflammation and Immunology
News
Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets
Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets
Research
Functionally-Guided Multiomics Profiling of Human Systemic Inflammation Identifies Myeloid Therapeutic Targets
Functionally-Guided Multiomics Profiling of Human Systemic Inflammation Identifies Myeloid Therapeutic Targets
Research
Graph partners with Parse Biosciences
Graph partners with Parse Biosciences
News
First data in RA - Cytodata 2025
First data in RA - Cytodata 2025
Research
Data Foundations of Precision Immunology
Data Foundations of Precision Immunology
Article
Graph and BIIE announce strategic collaboration to in precision immunology
Graph and BIIE announce strategic collaboration to in precision immunology
News
Graph awarded €1.1M Deep Tech Grant
Graph awarded €1.1M Deep Tech Grant
News
GTX co-founder appointed as Faculty Professor at the BIIE
GTX co-founder appointed as Faculty Professor at the BIIE
News
Graph Awarded €1.1M "Austrian Life Sciences" FFG Grant
Graph Awarded €1.1M "Austrian Life Sciences" FFG Grant
News
Graph Raises $3.1M Pre-Seed Round
Graph Raises $3.1M Pre-Seed Round
News
Copyright GraphTx 2026
Vienna, Asutria
Vienna, Austria
All system opperational